Boly Inc. Announces BolySolar Enhancer and Doubler Technology
Boly Inc., a global high-tech company headquartered in Silicon Valley, is pleased to announce its latest patent-pending technology for renewable energy at the Consumer Electronics Show 2017 (CES 2017) in Las Vegas.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005445/en/
BolySolar is an evolving set of solar system technologies created by Boly Inc. that will revolutionize the energy industry. At CES 2017, Boly Inc. will announce its fourth and fifth renewable energy products -- BolySolar Enhancer and BolySolar Doubler.
The patent-pending solutions utilize mirrors or reflective Fresnel lens technology to concentrate light into the focal area, which can be mounted directly to a solar panel. Both solutions are constructed to enhance current technology solar panel solutions. (See drawing)
BolySolar Enhancer has the following characteristics:
- It can be applied to existing installations to increase power generation, so as to recover investments costs sooner.
- Peak density is 1.3 times higher than existing fixed PV installations.
- It can generate 1.4 times more electricity than existing fixed PV installations annually.
- It can attach to existing fixed PV installations, with no need to re-arrange the panel layout.
- It is designed to be an aftermarket consumer product for utility and single panel solutions.
BolySolar Doubler, more powerful than the Enhancer, provides:
- A solution that will typically double the electricity output of a PV panel with flanking reflective Fresnel lens and mirrors
- 1.8-2 times annual electricity output boost for fixed PV installations
- Flexibility to attach to any solar panel, with or without a single axis tracking
- Option for low-cost single axis tracker with self-cleaning technology
These products will reduce costs by 20-30% and increase power production by 1.4-2.0 times. “With the current price of solar panels declining, our solution will bring costs down by a further 30% or more, and make higher-efficiency panels more economically attractive. This makes utility-scale solar power plants immediately more economical than fossil fuel power plants,” said Dr. Xiaoping Hu, CEO of Bolymedia Holdings Co. Ltd.
For more information about the latest technology of Boly Inc., please visit Booth 35785 at South Hall 4, CES 2017 which will last from January 5 to 8.
About Boly Inc.
Bolymedia Holdings Co. Ltd. (Boly Inc.) was established in 2002. The company has three subsidiary companies in California, Shenzhen and Hong Kong and has filed over 90 patents covering broad areas of Imaging and Clean Tech. The company has two business divisions, Imaging & Renewable Energy. Its mission is for the world to introduce efficient solar energy systems that solve the problem of global warming and remove the burdens of today’s energy struggles. For more information, please visit http://bolymedia.com/ .
Daniel Guo, +86-755-2685 4933
Director of Marketing
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
VERTEX-PHARMACEUTICALS19.10.2018 13:56 | pressemeddelelse
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene
TX-SCHLUMBERGER-LIMITED19.10.2018 13:02 | pressemeddelelse
Schlumberger Announces Third-Quarter 2018 Results
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum